Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm

Frances Boyle; Jane Beith; Katie Burslem; Richard de Boer; Rina Hui; Elgene Lim; Nicole McCarthy; Andrew Redfern; Natasha Woodward

doi:10.1111/ajco.13064

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm

Frances Boyle, Jane Beith, Katie Burslem, Richard de Boer, Rina Hui, Elgene Lim, Nicole McCarthy, Andrew Redfern, Natasha Woodward

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate in women with HR+ HER2- metastatic breast cancer compared with endocrine therapy alone. This review examines the clinical evidence to support the use of CDK4/6 inhibitors in first and second line settings. Practical guidance is provided for the use of CDK4/6 inhibitors, including tolerability data, monitoring requirements and management of key toxicities for each of the available agents.

Original language	English
Pages (from-to)	3-11
Number of pages	9
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	14 Suppl 4
DOIs	https://doi.org/10.1111/ajco.13064
Publication status	Published - Oct 2018
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/ajco.13064

Cite this

@article{c1b750aaadd448b291c709fc35ffae39,

title = "Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm",

abstract = "Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate in women with HR+ HER2- metastatic breast cancer compared with endocrine therapy alone. This review examines the clinical evidence to support the use of CDK4/6 inhibitors in first and second line settings. Practical guidance is provided for the use of CDK4/6 inhibitors, including tolerability data, monitoring requirements and management of key toxicities for each of the available agents.",

keywords = "Breast Neoplasms/genetics, Cyclin-Dependent Kinase 4/antagonists & inhibitors, Female, Humans, Receptor, ErbB-2/metabolism",

author = "Frances Boyle and Jane Beith and Katie Burslem and {de Boer}, Richard and Rina Hui and Elgene Lim and Nicole McCarthy and Andrew Redfern and Natasha Woodward",

year = "2018",

month = oct,

doi = "10.1111/ajco.13064",

language = "English",

volume = "14 Suppl 4",

pages = "3--11",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "John Wiley & Sons",

}

TY - JOUR

T1 - Hormone receptor positive, HER2 negative metastatic breast cancer

T2 - Impact of CDK4/6 inhibitors on the current treatment paradigm

AU - Boyle, Frances

AU - Beith, Jane

AU - Burslem, Katie

AU - de Boer, Richard

AU - Hui, Rina

AU - Lim, Elgene

AU - McCarthy, Nicole

AU - Redfern, Andrew

AU - Woodward, Natasha

PY - 2018/10

Y1 - 2018/10

N2 - Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate in women with HR+ HER2- metastatic breast cancer compared with endocrine therapy alone. This review examines the clinical evidence to support the use of CDK4/6 inhibitors in first and second line settings. Practical guidance is provided for the use of CDK4/6 inhibitors, including tolerability data, monitoring requirements and management of key toxicities for each of the available agents.

AB - Resistance to endocrine therapy is a significant therapeutic challenge in the treatment of women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Cyclin-dependent kinase (CDK)4/6 inhibitors in combination with endocrine therapy have been shown to improve progression free survival, overall response rate and clinical benefit rate in women with HR+ HER2- metastatic breast cancer compared with endocrine therapy alone. This review examines the clinical evidence to support the use of CDK4/6 inhibitors in first and second line settings. Practical guidance is provided for the use of CDK4/6 inhibitors, including tolerability data, monitoring requirements and management of key toxicities for each of the available agents.

KW - Breast Neoplasms/genetics

KW - Cyclin-Dependent Kinase 4/antagonists & inhibitors

KW - Female

KW - Humans

KW - Receptor, ErbB-2/metabolism

U2 - 10.1111/ajco.13064

DO - 10.1111/ajco.13064

M3 - Article

C2 - 30288930

SN - 1743-7555

VL - 14 Suppl 4

SP - 3

EP - 11

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

ER -

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this